Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
KT-253 by Kymera Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData,...
KT-253 by Kymera Therapeutics for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to...
KT-253 by Kymera Therapeutics for Uveal Melanoma: Likelihood of Approval
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Uveal Melanoma. According to GlobalData, Phase...
KT-253 by Kymera Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
KT-253 by Kymera Therapeutics for Sarcomas: Likelihood of Approval
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
KT-333 by Kymera Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
KT-333 by Kymera Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...
KT-333 by Kymera Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According to...
KT-333 by Kymera Therapeutics for T-Cell Lymphomas: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...
KT-333 by Kymera Therapeutics for Solid Tumor: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
KT-333 by Kymera Therapeutics for Head And Neck Cancer: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Head And Neck Cancer. According to...
KT-333 by Kymera Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
KT-333 by Kymera Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
KT-474 by Kymera Therapeutics for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
KT-474 is under clinical development by Kymera Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to...
KT-333 by Kymera Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...
KT-333 by Kymera Therapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData,...
KT-333 by Kymera Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
KT-474 by Kymera Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval
KT-474 is under clinical development by Kymera Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Kymera Therapeutics's KT-253?
KT-253 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Merkel Cell Carcinoma. According...